Johnson & Johnson is winding down its pharma division’s cardiovascular and metabolic unit, Endpoints News has learned.
The decision primarily impacts the sales, marketing and …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.